| Market Capitalization (Millions $) |
9 |
| Shares
Outstanding (Millions) |
44 |
| Employees |
18 |
| Revenues (TTM) (Millions $) |
- |
| Net Income (TTM) (Millions $) |
-25 |
| Cash Flow (TTM) (Millions $) |
0 |
| Capital Exp. (TTM) (Millions $) |
0 |
Business Description
Essa Pharma Inc. is a clinical-stage biopharmaceutical company that focuses on developing novel therapies for the treatment of cancer. The company is headquartered in Vancouver, British Columbia, Canada, and was formed in 2009.
Essa Pharma primarily focuses on developing therapies that inhibit the androgen receptor and associated pathways, which are known to play a significant role in the development and progression of castration-resistant prostate cancer (CRPC). Their lead product candidate, EPI-7386, is currently under clinical investigation for the treatment of metastatic CRPC.
Essa Pharma has also developed a proprietary platform technology, called AP-01, which enables the identification of small molecules that are specific to oncogenic proteins, which could be developed into cancer therapeutics.
The company has partnerships and collaborations with different organizations to accelerate the development of their products. For instance, the company has a partnership with the University of California Los Angeles (UCLA) to investigate the use of their product, EPI-7386, in clinical trials for the treatment of advanced prostate cancer.
Overall, Essa Pharma is a clinical-stage biopharmaceutical company that is working towards developing innovative therapies for the treatment of cancer. The company has a strong pipeline of products and collaborations with leading academic institutions, which makes them a promising player in the biopharmaceutical industry.
Company Address: Suite 720 Vancouver 0 BC
Company Phone Number: 331-0962 Stock Exchange / Ticker: NASDAQ EPIX
|
